[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Tumor Genomics Market: Focus on Products, Techniques, Applications, End User, Cancer Type, 14 Countries Data, Industry Insights and Competitive Landscape - Analysis and Forecast, 2019-2028

May 2020 | 259 pages | ID: GAFB9F546117EN
BIS Research Inc.

US$ 5,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Market Report Coverage - Tumor Genomics

Market Segmentation
  • By Product: Assays and Kits, and Instruments
  • By Technique: Next Generation Sequencing Technique (NGS), Polymerase Chain Reaction (PCR), Microarray, In-Situ Hybridization (ISH), Immunohistochemistry (ICH), Others (Mass Spectrometry and Flow Cytometry)
  • By Application: Diagnostics and Monitoring, Drug Discovery and Development, and Biomarker Discovery
  • By End User: Academics and Research Organizations, Hospitals and Ambulatory Clinics, Clinical and Diagnostic Laboratories, and Biotechnology and Pharmaceutical Company
  • By Cancer Type: Leukemia, Breast Cancer, Melanoma, Colon Cancer, Lung Cancer, Prostate Cancer, Head and Neck Cancer, and Others (Ovarian, Pancreatic, and Testicular)
Regional Segmentation
  • North America – U.S., Canada
  • Europe – Germany, U.K., France, Italy, Spain, Netherlands, Rest-of-Europe
  • Asia-Pacific – Japan, China, Australia, India, Rest-of-Asia-Pacific
  • Rest-of-the-World – Latin America and Middle East & Africa
Growth Drivers
  • Rising Government Initiatives and Projects
  • Increasing Incidence of Cancer
  • Increasing Number of Product Approvals and Launches
  • Ever Expanding Application Areas for Genomics
  • Increasing Use of Biomarkers in Cancer Profiling
Market Challenges
  • High Cost of Genomic Equipment
  • Lack of Unified Framework for Data Integration
Market Opportunities
  • Growing Prominence for Precision Medicine
  • Increasing Demand for Point-of-Care Diagnostics
Key Companies Profiled

Thermo Fisher Scientific Inc., Illumina, Inc., QIAGEN, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Merck KGaA, Pacific Biosciences of California, Inc., Myriad Genetics, Inc., and PerkinElmer.

Key Questions Answered:
  • What is tumor genomics? How the different tumor genomic techniques have evolved over the years?
  • What are the major market drivers, challenges, and opportunities in the global tumor genomics market?
  • What was the global tumor genomics market size in terms of revenue in 2019? How is the market expected to evolve in the upcoming years? What is the market size expected to be in 2028?
  • How is each segment of the global tumor genomics market expected to grow during the forecast period between 2020 to 2028 and what is the revenue expected to be generated by each of the segments by the end of 2028?
  • What are the developmental strategies implemented by the key players to sustain in the competitive market?
  • What is the growth potential of the tumor genomics market in each region, namely, North America, Europe, Asia-Pacific, and the Rest-of-the-World?
  • Which product among the two (assays and kits & instrument) are offered by key players such as Thermo Fisher Scientific, Illumina Inc., Qiagen N.V., and F. Hoffmann-La Roche Ltd.?
  • Which technique is leading the market in 2018 and expected to dominate the market in 2028 and why?
  • Which application and end user type are leading the market in 2019 and are expected to dominate the market in 2028 and why?
  • Which region dominated the global tumor genomics market in 2019 and what are the expected trends from each of the regions in the forecast period 2020-2028?
Market Overview

In order to meet the growing product demand and need, companies are investing in the assays, kits, and instruments used in tumor genomics. Nowadays, large number of kits and reagents are used to test the profiling of mutated genes. For instance, companies such as Thermo Fisher Scientific, Illumina, Inc., and QIAGEN N.V. have focused on the development of variety of kits for the detection of rare genetic diseases due to cost-effectiveness of the kit as compared to instrument and software, which in turn is causing widespread utilization of kits globally.

The market is also witnessing the launches of various products by receiving FDA approvals such as assay for the study of genes and molecular characterization of DNA. For instance, on, January 16, 2019, QIAGEN received approval from Japanese Pharmaceuticals and Medical Device Agency (PMDA) on therascreen EGFR RGQ PCR Kit which is used as a companion diagnostic for lung cancer patients on treatment with Dacomitinib.

Similarly, several manufacturers are also launching innovative products to expand their offerings in the market. For instance, on November 6, 2019, Thermo Fisher Scientific launched Ion Torrent Genexus System, which is a fully integrated next generation sequencing platform used for profiling of genomes.

The market is favored by multiple factors, which include rising government initiatives, increasing incidence of cancer, therefore increasing the utilization of sequencing to identify the mutant DNA segments, increasing number of product approvals and launches pertaining to genomics market. Moreover, increasing use of biomarkers in cancer profiling is also one of the key driving factors for tumor genomics market.

Government funding is also one of the major growth factors for tumor genomics market, because increasing funding by the government help the research institutes to develop sequencing systems useful for the diagnosis of genetic diseases. Increasing funding shall lead to liquidity of the genomics market and thus companies shall develop various sequencing systems to identify the mutation in the segments of DNA. All these factors are thus expected to contribute to the market growth during the forecast period.

Within the research report, the market is segmented on the basis of product type, techniques, application, end user, cancer type, and region, which highlight value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide a 360-coverage of the domain.

Competitive Landscape

Major players including QIAGEN N.V., Illumina, Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd. Thermo Fisher Scientific, and BGI, among others, led the number of synergistic developments (partnerships and alliances) witnessed by the market. On the basis of region, North America is expected to retain a leading position throughout the forecast period 2019-2029, followed by Europe. This is a result of the presence of leading industry players in these regions, and a higher adoption rate of sequencing system to detect the mutation in genes and DNA segments. Moreover, growing research in the field of sequencing technologies including next-generation sequencing technologies (NGS) is one of the drivers that promote the growth of the tumor genomics market.
EXECUTIVE SUMMARY

1 PRODUCT DEFINITION

1.1 Inclusion and Exclusion

2 RESEARCH SCOPE

2.1 Scope of the Study
2.2 Key Questions Answered in the Report

3 RESEARCH METHODOLOGY

3.1 Global Tumor Genomics: Research Methodology
3.2 Primary Data Sources
3.3 Secondary data sources
3.4 Data Triangulation
3.5 Segmentation of the Global Tumor Genomics Market
3.6 Inclusion and Exclusion
3.7 Base Year and Forecast Year

4 GLOBAL TUMOR GENOMICS MARKET

4.1 Market Overview
4.2 Introduction to Tumor Genomics
4.3 Evolution of Tumor Genomic Techniques
4.4 Global Market Scenario and Key Technology Trends

5 MARKET DYNAMICS

5.1 Introduction
5.2 Impact Analysis
5.3 Market Drivers
  5.3.1 Rising Government Initiatives and Projects
  5.3.2 Increasing Incidence of Cancer
  5.3.3 Increasing Number of Product Approval and Launches
  5.3.4 Ever Expanding Application Areas for Genomics
  5.3.5 Increasing Use of Biomarkers in Cancer Profiling
5.4 Market Restraints
  5.4.1 High Cost of Genomic Equipment
  5.4.2 Lack of Unified Framework for Data Integration
5.5 Market Opportunities
  5.5.1 Growing Prominence for Precision Medicine
  5.5.2 Increasing Demand for Point-of-Care Diagnostics

6 INDUSTRY INSIGHTS

6.1 Regulatory Requirements
  6.1.1 Regulatory Framework in the U.S.
    6.1.1.1 Guidelines Published in FY2018
    6.1.1.2 Guidelines Published in FY2016
  6.1.2 Europe
  6.1.3 Japan
6.2 Patent Analysis

7 COMPETITIVE LANDSCAPE

7.1 Key Developments and Strategies
  7.1.1 Partnerships and Alliances
  7.1.2 New Product Launches
  7.1.3 Mergers and Acquisition Activities
  7.1.4 Business Expansions
  7.1.5 Others
7.2 Market Share Analysis
  7.2.1 Market Share Analysis (by Company)
7.3 Growth Share Analysis
  7.3.1 Growth Share Matrix (by Company)

8 GLOBAL TUMOR GENOMICS MARKET (BY PRODUCT)

8.1 Assays and Kits
8.2 Instrument

9 GLOBAL TUMOR GENOMICS MARKET (BY TECHNIQUE)

9.1 Next Generation Sequencing (NGS)
9.2 Polymerase Chain Reaction (PCR)
9.3 Microarray
9.4 In-Situ Hybridization (ISH)
9.5 Immunohistochemistry (IHC)
9.6 Other Technologies (Mass Spectrometry and Flow Cytometry)

10 GLOBAL TUMOR GENOMICS MARKET (BY APPLICATION)

10.1 Diagnostics and Monitoring
10.2 Drug Discovery and Development
10.3 Biomarker Discovery

11 GLOBAL TUMOR GENOMICS MARKET (BY END USER)

11.1 Academics and Research Organizations
11.2 Hospitals and Ambulatory Clinics
11.3 Clinical and Diagnostic Laboratories
11.4 Biotechnology and Pharmaceutical Companies

12 GLOBAL TUMOR GENOMICS MARKET (BY CANCER TYPE)

12.1 Leukemia
12.2 Breast Cancer
12.3 Melanoma
12.4 Colon Cancer
12.5 Lung Cancer
12.6 Prostate Cancer
12.7 Head and Neck Cancer
12.8 Others (Ovarian, Pancreatic, and Testicular)

13 GLOBAL TUMOR GENOMICS MARKET (BY REGION)

13.1 North America
  13.1.1 North America Tumor Genomics Market (by Country)
  13.1.2 U.S.
  13.1.3 Canada
13.2 Europe
  13.2.1 Europe Tumor Genomics Market (by Country)
  13.2.2 Germany
  13.2.3 U.K.
  13.2.4 France
  13.2.5 Italy
  13.2.6 Spain
  13.2.7 Netherlands
  13.2.8 Rest-of-Europe
13.3 Asia-Pacific (APAC)
  13.3.1 Asia-Pacific Tumor Genomics Market (by Country)
  13.3.2 China
  13.3.3 Japan
  13.3.4 Australia
  13.3.5 India
  13.3.6 Rest-of-Asia-Pacific
13.4 Rest-of-the-World
  13.4.1 Rest-of-the-World Tumor Genomics Market (by Country)
  13.4.2 Latin America
  13.4.3 Middle East & Africa

14 COMPANY PROFILES

14.1 Abbott Laboratories
  14.1.1 Company Overview
  14.1.2 Role of Abbott Laboratories in the Global Tumor Genomics Market
  14.1.3 Financials
  14.1.4 Key Insights About Financial Health of the Company
  14.1.5 SWOT Analysis
14.2 Agilent Technologies, Inc.
  14.2.1 Company Overview
  14.2.2 Role of Agilent Technologies, Inc. in the Global Tumor Genomics Market
  14.2.3 Financials
  14.2.4 Key Insights About Financial Health of the Company
  14.2.5 SWOT Analysis
14.3 Bio-Rad Laboratories, Inc.
  14.3.1 Company Overview
  14.3.2 Role of Bio-Rad Laboratories, Inc. in the Global Tumor Genomics Market
  14.3.3 Financials
  14.3.4 Key Insights About Financial Health of the Company
  14.3.5 SWOT Analysis
14.4 Danaher Corporation
  14.4.1 Company Overview
  14.4.2 Role of Danaher Corporation in the Global Tumor Genomics Market
  14.4.3 Financials
  14.4.4 Key Insights About Financial Health of the Company
  14.4.5 SWOT Analysis
14.5 F. Hoffmann-La Roche Ltd
  14.5.1 Company Overview
  14.5.2 Role of F. Hoffmann-La Roche Ltd in the Global Tumor Genomics Market
  14.5.3 Financials
  14.5.4 Key Insights About Financial Health of the Company
  14.5.5 SWOT Analysis
14.6 Fluidigm Corporation
  14.6.1 Company Overview
  14.6.2 Role of Fluidigm Corporation in the Global Tumor Genomics Market
  14.6.3 Financials
  14.6.4 Key Insights About Financial Health of the Company
  14.6.5 SWOT Analysis
14.7 General Electric Company
  14.7.1 Company Overview
  14.7.2 Role of General Electric Company in the Global Tumor Genomics Market
  14.7.3 Financials
  14.7.4 Key Insights About Financial Health of the Company
  14.7.5 SWOT Analysis
14.8 Illumina, Inc.
  14.8.1 Company Overview
  14.8.2 Role of Illumina, Inc. in the Global Tumor Genomic Market
  14.8.3 Financials
  14.8.4 Key Insights About Financial Health of the Company
  14.8.5 SWOT Analysis
14.9 Merck KGaA
  14.9.1 Company Overview
  14.9.2 Role of Merck KGaA in the Global Tumor Genomics Market
  14.9.3 Financials
  14.9.4 Key Insights About Financial Health of the Company
  14.9.5 SWOT Analysis
14.10 Myriad Genetics, Inc.
  14.10.1 Company Overview
  14.10.2 Role of Myriad Genetics, Inc. in the Global Tumor Genomics Market
  14.10.3 Financials
  14.10.4 Key Insights About Financial Health of the Company
  14.10.5 SWOT Analysis
14.11 Pacific Biosciences of California, Inc.
  14.11.1 Company Overview
  14.11.2 Role of Pacific Biosciences of California, Inc. in the Global Tumor Genomics Market
  14.11.3 Financials
  14.11.4 Key Insights About Financial Health of the Company
  14.11.5 SWOT Analysis
14.12 PerkinElmer
  14.12.1 Company Overview
  14.12.2 Role of PerkinElmer in the Global Tumor Genomics Market
  14.12.3 Financials
  14.12.4 Key Insights about Financial Health of the Company
  14.12.5 SWOT Analysis
14.13 QIAGEN
  14.13.1 Company Overview
  14.13.2 Role of QIAGEN in the Global Tumor Genomics Market
  14.13.3 Financials
  14.13.4 Key Insights about Financial Health of the Company
  14.13.5 SWOT Analysis
14.14 Siemens Healthineers AG
  14.14.1 Company Overview
  14.14.2 Role of Siemens Healthineers AG in the Global Tumor Genomics Market
  14.14.3 Financials
  14.14.4 Key Insights about Financial Health of the Company
  14.14.5 SWOT Analysis
14.15 Thermo Fisher Scientific Inc.
  14.15.1 Company Overview
  14.15.2 Role of Thermo Fisher Scientific Inc. in the Global Tumor Genomics Market
  14.15.3 Financials
  14.15.4 Key Insights on the Financial Health of the Company
  14.15.5 SWOT Analysis

LIST OF TABLES

Table 1: Key Product Launches Between May 2017-February 2020
Table 5.1: Impact Analysis of Market Drivers
Table 5.2: Impact analysis of Market Restraints
Table 5.3: Number of Product Launches (2018-2020)
Table 5.4: Number of Product Approvals (2018 and 2019)
Table 6.1: List of Major Regulatory Bodies and Associations across the World
Table 6.2: Global Tumor Genomics Market: Patent Analysis
Table 8.1: Competitive Benchmarking by Product and Technique

LIST OF FIGURES

Figure 1: Percentage of Cancer Deaths, by Type: 2007-2020
Figure 2: Global Tumor Genomics Market Value, 2018-2028
Figure 3: Drivers and Restraints of Global Tumor Genomics Market
Figure 4: Share of Key Developments and Strategies, January 2017-February 2020
Figure 5: Global Tumor Genomics Market (by Product), 2018-2028
Figure 6: Global Tumor Genomics Market (by Technique), 2018-2028
Figure 7: Global Tumor Genomics Market (by Application), 2018-2028
Figure 8: Global Tumor Genomics Market (by End User), 2018-2028
Figure 9: Global Tumor Genomics Market (by Cancer Type), 2018-2028
Figure 10: Global Tumor Genomics Market (by Region): 2019 and 2028
Figure 3.1: Global Tumor Genomics Market Research Methodology
Figure 3.2: Primary Research
Figure 3.3: Secondary Research
Figure 3.4: Data Triangulation
Figure 3.5: Top-Down Approach (Segment-Wise Analysis)
Figure 3.6: Bottom-up Approach (Segment-Wise Analysis)
Figure 3.7: Assumptions and Limitations
Figure 3.8: Assumptions and Limitations
Figure 3.9: Segmentation of the Global Tumor Genomics Market
Figure 4.1: Evolution of Tumor Genomic Techniques
Figure 4.2: Global Tumor Genomics Market Size, 2018-2028
Figure 5.1: Incidence of Different Cancers (2014-2017)
Figure 7.1: Competitive Landscape, January 2017-February 2020
Figure 7.2: Share of Key Developments and Strategies, January 2017-February 2020
Figure 7.3: Partnerships and Alliances (by Company), January 2017-February 2020
Figure 7.4: New Product Launches (by Company), January 2017-February 2020
Figure 7.5: Others (by Company), January 2017-February 2020
Figure 7.6: Market Share Analysis for the Global Tumor Genomics Market, by Company (2019)
Figure 7.7: Growth Share Matrix: Global Tumor Genomics Market (by Company), 2018-2019
Figure 8.1: Global Tumor Genomics Market (by Product)
Figure 8.2: Global Tumor Genomics Market (by Product), 2018-2028
Figure 8.3: Global Tumor Genomics Market for Assays and Kits, 2018-2028
Figure 8.4: Global Tumor Genomics Market for Instruments, 2018-2028
Figure 9.1: Global Tumor Genomics Market, by Techniques
Figure 9.2: Global Tumor Genomics Market (by Technique), 2018-2028
Figure 9.3: Global Tumor Genomics Market (Technique: Next-Generation Sequencing), 2018-2028
Figure 9.4: Global Tumor Genomics Market (Technique: Polymerase Chain Reaction), 2018-2028
Figure 9.5: Global Tumor Genomics Market (Technique: Microarray) , 2018-2028
Figure 9.6: Global Tumor Genomics Market (Technique: In-Situ Hybridization), 2018-2028
Figure 9.7: Global Tumor Genomics Market (Technique: Immunohistochemistry), 2018-2028
Figure 9.8: Global Tumor Genomics Market (Technique: Other Technologies {Mass Spectrometry and Flow Cytometry}), 2018-2028
Figure 10.1: Global Tumor Genomics Market, by Application
Figure 10.2: Global Tumor Genomics Market (by Application), 2018-2028
Figure 10.3: Global Tumor Genomics Market (Application: Diagnostics and Monitoring), 2018-2028
Figure 10.4: Global Tumor Genomics Market (Application: Drug Discovery and Development), 2018-2028
Figure 10.5: Global Tumor Genomics Market (Application: Biomarker Discovery), 2018-2028
Figure 11.1: Global Tumor Genomics Market, by End User
Figure 11.2: Global Tumor Genomics Market (by End User), 2018-2028
Figure 11.3: Global Tumor Genomics Market (End User: Academics and Research Organizations), 2018-2028
Figure 11.4: Global Tumor Genomics Market (End User: Hospitals and Ambulatory Clinics), 2018-2028
Figure 11.5: Global Tumor Genomics Market (End User: Clinical and Diagnostic Laboratories), 2018-2028
Figure 11.6: Global Tumor Genomics Market (End User: Biotechnology and Pharmaceutical Company), 2018-2028
Figure 12.1: Global Tumor Genomics Market, by Cancer Type
Figure 12.2: Global Tumor Genomics Market (by Cancer Type), 2018-2028
Figure 12.3: Global Tumor Genomics Market (Cancer Type: Leukemia), 2018-2028
Figure 12.4: Global Tumor Genomics Market (Cancer Type: Breast Cancer), 2018-2028
Figure 12.5: Global Tumor Genomics Market (Cancer Type: Melanoma), 2018-2028
Figure 12.6: Global Tumor Genomics Market (Cancer Type: Colon Cancer), 2018-2028
Figure 12.7: Global Tumor Genomics Market (Cancer Type: Lung Cancer), 2018-2028
Figure 12.8: Global Tumor Genomics Market (Cancer Type: Prostate Cancer), 2018-2028
Figure 12.9: Global Tumor Genomics Market (Cancer Type: Head and Neck Cancer), 2018-2028
Figure 12.10: Global Tumor Genomics Market (Cancer Type: Others {Ovarian, Pancreatic, and Testicular}), 2018-2028
Figure 13.1: Global Tumor Genomics Market (by Region), 2019 and 2028
Figure 13.2: North America Tumor Genomics Market, 2018-2028
Figure 13.3: North America: Market Dynamics
Figure 13.4: North America Tumor Genomics Market (by Country), 2019 and 2028
Figure 13.5: U.S. Tumor Genomics Market, 2018-2028
Figure 13.6: Canada: Tumor Genomics Market, 2018-2028
Figure 13.7: Europe: Tumor Genomics Market, 2018-2028
Figure 13.8: Europe: Market Dynamics
Figure 13.9: Europe Tumor Genomics Market (by Country), 2019 and 2028
Figure 13.10: Germany Tumor Genomics Market, 2018-2028
Figure 13.11: U.K. Tumor Genomics Market, 2018-2028
Figure 13.12: France Tumor Genomics Market, 2018-2028
Figure 13.13: Italy Tumor Genomics Market, 2018-2028
Figure 13.14: Spain Tumor Genomics Market, 2018-2028
Figure 13.15: Netherlands Tumor Genomics Market, 2018-2028
Figure 13.16: Rest-of-Europe Tumor Genomics Market, 2018-2028
Figure 13.17: Asia-Pacific: Tumor Genomics Market, 2018-2028
Figure 13.18: Asia-Pacific: Market Dynamics
Figure 13.19: Asia-PacificTumor Genomics Market (by Country), 2019 and 2028
Figure 13.20: China Tumor Genomics Market, 2018-2028
Figure 13.21: Japan Tumor Genomics Market, 2018-2028
Figure 13.22: Australia Tumor Genomics Market, 2018-2028
Figure 13.23: India Tumor Genomics Market, 2018-2028
Figure 13.24: Rest-of-Asia-Pacific Tumor Genomics Market, 2018-2028
Figure 13.25: Rest-of-the-World Tumor Genomics Market, 2018-2028
Figure 13.26: Rest-of-the-World (RoW): Market Dynamics
Figure 13.27: Rest-of-the-World Tumor Genomics Market (by Country), 2019 and 2028
Figure 13.28: Latin America Tumor Genomics Market, 2018-2028
Figure 13.29: Middle East & Africa Tumor Genomics Market, 2018-2028
Figure 14.1: Abbott Laboratories: Product Offerings for the Global Tumor Genomics Market
Figure 14.2: Abbott Laboratories: Overall Financials, 2017-2019
Figure 14.3: Abbott Laboratories: Revenue (by Product/Service), 2017-2019
Figure 14.4: Abbott Laboratories: Revenue (by Region), 2017-2019
Figure 14.5: Abbott Laboratories: R&D Expenditure, 2017-2019
Figure 14.6: Abbott Laboratories: SWOT Analysis
Figure 14.7: Agilent Technologies, Inc.: Product Offerings for the Global Tumor Genomics Market
Figure 14.8: Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 14.9: Agilent Technologies, Inc.: Revenue (by Business Model), 2017-2019
Figure 14.10: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 14.11: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 14.12: Agilent Technologies, Inc.: SWOT Analysis
Figure 14.13: Bio-Rad Laboratories, Inc.: Product Offerings for the Global Tumor Genomics Market
Figure 14.14: Bio-Rad Laboratories, Inc.: Overall Financials, 2016-2018
Figure 14.15: Bio-Rad Laboratories, Inc.: Revenue (by Product/Service), 2016-2018
Figure 14.16: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2016-2018
Figure 14.17: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2016-2018
Figure 14.18: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 14.19: Danaher Corporation Product Offerings for the Global Tumor Genomics Market
Figure 14.20: Danaher Corporation: Overall Financials, 2017-2019
Figure 14.21: Danaher Corporation: Revenue (by Product/Service), 2017-2019
Figure 14.22: Danaher Corporation: Revenue (by Region), 2017-2019
Figure 14.23: Danaher Corporation: R&D Expenditure, 2017-2019
Figure 14.24: Danaher Corporation: SWOT Analysis
Figure 14.25: F. Hoffman-La-Roche Ltd: Product Offerings for the Global Tumor Genomics Market
Figure 14.26: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 14.27: F. Hoffmann-La Roche Ltd: Revenue (by Product/Service), 2017-2019
Figure 14.28: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
Figure 14.29: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2018-2018
Figure 14.30: F. Hoffmann-La Roche AG: SWOT Analysis
Figure 14.31: Fluidigm Corporation: Overall Product Portfolio
Figure 14.32: Fluidigm Corporation: Overall Financials, 2017-2019
Figure 14.33: Fluidigm Corporation: Revenue (by Business Segment), 2016-2018
Figure 14.34: Fluidigm Corporation: Revenue (by Region), 2016-2018
Figure 14.35: Fluidigm Corporation: R&D Expenditure, 2016-2018
Figure 14.36: Fluidigm Corporation: SWOT Analysis
Figure 14.37: General Electric Company: Product Offerings for the Global Tumor Genomics Market
Figure 14.38: General Electric Company: Overall Financials, 2017-2019
Figure 14.39: General Electric Company: Revenue (by Business Model), 2017-2019
Figure 14.40: General Electric Company: Revenue (by Region), 2017-2019
Figure 14.41: General Electric Company: R&D Expenditure, 2017-2019
Figure 14.42: General Electric Company: SWOT Analysis
Figure 14.43: Illumina, Inc.: Product Offerings for the Global Tumor Genomics Market
Figure 14.44: Illumina, Inc.: Overall Financials, 2016-2018
Figure 14.45: Illumina Inc.: Revenue (by Segment), 2016-2018
Figure 14.46: Illumina, Inc.: Revenue (by Region), 2016-2018
Figure 14.47: Illumina, Inc.: R&D Expenditure, 2016-2018
Figure 14.48: Illumina, Inc.: SWOT Analysis
Figure 14.49: Merck KGaA: Product Offerings for the Global Tumor Genomics Market
Figure 14.50: Merck KGaA: Overall Financials, 2017-2019
Figure 14.51: Merck KGaA: Revenue (by Product/Service), 2017-2019
Figure 14.52: Merck KGaA: Revenue (by Region), 2017-2019
Figure 14.53: Merck KGaA: R&D Expenditure, 2017-2019
Figure 14.54: Merck KGaA: SWOT Analysis
Figure 14.55: Myriad Genetics, Inc.: Product Offerings for the Global Tumor Genomics Market
Figure 14.56: Myriad Genetics, Inc.: Overall Financials, 2017-2019
Figure 14.57: Myriad Genetics, Inc.: Revenue (by Product/Service), 2017-2019
Figure 14.58: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
Figure 14.59: Myriad Genetics, Inc.: SWOT Analysis
Figure 14.60: Bio-Rad Laboratories, Inc.: Overall Product Portfolio
Figure 14.61: Pacific Biosciences of California, Inc.: Overall Financials, 2016-2018
Figure 14.62: Pacific Biosciences of California, Inc.: Revenue (by Product/Service), 2016-2018
Figure 14.63: Pacific Biosciences of California, Inc.: Revenue (by Region), 2016-2018
Figure 14.64: Pacific Biosciences of California, Inc.: R&D Expenditure, 2016-2018
Figure 14.65: Pacific Biosciences: SWOT Analysis
Figure 14.66: PerkinElmer: Product Offerings for the Global Tumor Genomics Market
Figure 14.67: Perkin Elmer: Overall Financials, 2017-2019
Figure 14.68: PerkinElmer: Revenue (by Products & Services), 2017-2019
Figure 14.69: PerkinElmer: Revenue (by Region), 2017-2019
Figure 14.70: PerkinElmer: R&D Expenditure, 2017-2019
Figure 14.71: PerkinElmer lnc.: SWOT Analysis
Figure 14.72: QIAGEN: Product Offerings for the Global Tumor Genomics Market
Figure 14.73: QIAGEN: Overall Financials, 2016-2018
Figure 14.74: QIAGEN: Revenue (by Business Model), 2016-2018
Figure 14.75: QIAGEN: Revenue (by Region), 2016-2018
Figure 14.76: QIAGEN: R&D Expenditure, 2016-2018
Figure 14.77: QIAGEN: SWOT Analysis
Figure 14.78: Siemens Healthineers AG: Product Offerings for the Global Tumor Genomics Market
Figure 14.79: Siemens Healthineers AG Overall Financials, 2017-2019
Figure 14.80: Siemens Healthineers AG: Revenue (by Product and Services), 2017-2019
Figure 14.81: Siemens Healthineers AG: Revenue (by Region), 2017-2019
Figure 14.82: Siemens Healthineers AG: R&D Expenditure, 2017-2019
Figure 14.83: Siemens Healthineers AG: SWOT Analysis
Figure 14.84: Thermo Fisher Scientific Inc.: Product Offerings for the Global Tumor Genomics Market
Figure 14.85: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
Figure 14.86: Thermo Fisher Scientific Inc.: Net Revenue (by Business Segment), 2017-2019
Figure 14.87: Thermo Fisher Scientific Inc.: Net Revenue (by Region), 2017-2019
Figure 14.88: Thermo Fisher Scientific Inc.: R&D Expense, 2017-2019
Figure 14.89: Thermo Fisher Scientific, Inc.: SWOT Analysis


More Publications